Earnings ·
Xencor reported second quarter 2026 financial results with revenue of $51.2 million and a net loss of $21.7 million…
XNCRXencor Inc
Xencor reported second quarter 2026 financial results with revenue of $51.2 million and a net loss of $21.7 million, or $(0.29) per diluted share. Revenue increased from $43.6 million in the prior year period, driven by milestone payments from Zenas BioPharma and royalties from Alexion following a settlement agreement that resolved a dispute over U.S. Ultomiris sales rights. Research and development expenses rose to $71.9 million due to increased pipeline spending, while general and administrative costs remained stable at $16.4 million. The company holds $486.4 million in cash and expects sufficient resources to fund operations through 2028. Pipeline updates include enrollment for XmAb819 expansion cohorts, on-track XENITH-UC study progress for XmAb942, and the initiation of a Phase 1 study for XmAb412. Xencor is a clinical-stage biopharmaceutical company developing engineered antibodies for cancer and autoimmune diseases.